Sutro Biopharma, Inc. experienced a net loss of $75.968 million in Q1 2025, an increase from the $58.213 million loss in Q1 2024. Total revenue grew by 34% to $17.399 million, largely due to increased revenue from the Astellas Agreement. Operating expenses rose by 23% to $85.913 million, primarily due to restructuring costs.

Sutro Biopharma reported a net loss of $227.461 million for the full year 2024, with total revenues of $62.043 million. The company announced a strategic portfolio review, prioritizing next-generation ADC programs, and expects a cash runway into at least Q4 2026.

Sutro Biopharma reported $8.5 million in revenue for Q3 2024, with cash, cash equivalents, and marketable securities totaling $388.3 million as of September 30, 2024. The company is advancing its lead program, luveltamab tazevibulin (luvelta), with ongoing clinical trials and plans for multiple IND filings in the coming years.

Sutro Biopharma reported revenue of $25.7 million for Q2 2024, compared to $10.4 million for the same period in 2023. The company's cash, cash equivalents, and marketable securities totaled $426.0 million as of June 30, 2024.

Sutro Biopharma reported revenue of $13.0 million for Q1 2024, primarily from the Astellas collaboration, Tasly, and Vaxcyte agreements. The company's cash position was bolstered by upfront payments and an equity investment from licensing STRO-003 to Ipsen and proceeds from an underwritten offering of common stock.

Sutro Biopharma reported its full year 2023 financial results, highlighting the initiation of the REFRαME-O1 study of luvelta and the advancement of earlier stage programs. The company also strengthened its management team and cash position.

Sutro Biopharma reported its Q3 2023 financial results, business highlights, and a preview of select anticipated milestones. The company had cash and investments of $321.1 million and shares of Vaxcyte common stock valued at $34.0 million as of September 30, 2023, providing a projected cash runway into the first half of 2025. Revenue for the quarter was $16.9 million, and total operating expenses were $60.9 million.

Sutro Biopharma reported its Q2 2023 financial results, highlighting the initiation of the REFRaME study for platinum-resistant ovarian cancer and the royalty monetization agreement with Blackstone Life Sciences, which provided an upfront payment of $140 million. The company's cash runway extends into the first half of 2025, supported by cash, investments, and Vaxcyte common stock valued at $358.3 million and $33.3 million, respectively.

Sutro Biopharma reported a revenue of $12.7 million for Q1 2023, primarily from collaborations with Astellas, Merck, and BMS. The company's cash and investments totaled $251.5 million, with Vaxcyte common stock valued at $25.0 million, providing a cash runway into the second half of 2024. Sutro plans to initiate REFRaME, a registration-directed trial for luveltamab tazevibulin.

Sutro Biopharma reported full year 2022 financial results, highlighting significant milestones in their pipeline and collaborations, and the appointment of Anne Borgman as Chief Medical Officer.

Sutro Biopharma reported revenue of $25.1 million for the quarter ended September 30, 2022, and had cash, cash equivalents and marketable securities of $287.3 million as of September 30, 2022. The company's cash runway is projected into the first half of 2024.

Sutro Biopharma reported its Q2 2022 financial results, highlighting a collaboration with Astellas, a milestone payment from Merck, and discussions with the FDA regarding accelerated approval for STRO-002. The company's cash, cash equivalents, and marketable securities totaled $191.6 million as of June 30, 2022, with revenue of $28.1 million for the quarter.

Sutro Biopharma reported its financial results for the quarter ended March 31, 2022. The company's cash, cash equivalents and marketable securities totaled $192.1 million as of March 31, 2022, with projected cash runway into the second half of 2023. Revenue was $5.9 million for the quarter ended March 31, 2022.

Sutro Biopharma reported cash, cash equivalents and marketable securities totaling $229.5 million as of December 31, 2021, with projected cash runway into the second half of 2023. Revenue was $61.9 million for the year ended December 31, 2021. Total operating expenses for the year ended December 31, 2021 were $160.4 million.

Sutro Biopharma reported revenue of $8.5 million for the third quarter of 2021. The company's cash, cash equivalents, and marketable securities totaled $254.2 million as of September 30, 2021, projecting a cash runway into the second half of 2023.

Sutro Biopharma reported revenue of $28.0 million for the second quarter of 2021, primarily related to collaborations with Merck, BMS, and EMD Serono. The company's cash, cash equivalents, and marketable securities totaled $283.4 million as of June 30, 2021.

Sutro Biopharma reported revenue of $14.7 million for the quarter ended March 31, 2021, and cash, cash equivalents and marketable securities of $294.9 million as of March 31, 2021. The company anticipates that the cash runway will last into the second half of 2023.

Sutro Biopharma reported full year 2020 financial results, highlighting a net cash increase of $193.0 million during 2020 and year-end cash, cash equivalents and marketable securities of $326.5 million. The company also progressed its clinical development programs and collaborations with partners like Merck, Bristol Myers Squibb, and EMD Serono.

Sutro Biopharma reported revenue of $17.8 million and a net income of $17.1 million for the third quarter of 2020. The company's cash, cash equivalents, and marketable securities totaled $202.4 million as of September 30, 2020.

Sutro Biopharma reported its Q2 2020 financial results, highlighting the progress of its STRO-001 and STRO-002 clinical trials and collaborations with Merck KGaA, Bristol Myers Squibb and EMD Serono. The company reported net income of $29.9 million due to an unrealized gain on Vaxcyte common stock.

Sutro Biopharma reported revenue of $7.2 million for the quarter ended March 31, 2020, compared to $8.6 million in the corresponding 2019 quarter. The company's cash, cash equivalents and marketable securities were $129.6 million as of March 31, 2020, compared to $133.5 million as of December 31, 2019.

Sutro Biopharma, Inc. reported its financial results for the year ended December 31, 2019. The company had cash, cash equivalents and marketable securities of $133.5 million as of December 31, 2019, and revenue of $42.7 million for the year ended December 31, 2019.